Gena Wang
Stock Analyst at Barclays
(3.11)
# 1,287
Out of 4,996 analysts
221
Total ratings
44.44%
Success rate
1.03%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Gena Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KOD Kodiak Sciences | Upgrades: Equal-Weight | $7 → $17 | $15.80 | +7.59% | 10 | Sep 25, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Overweight | $78 → $80 | $64.09 | +24.82% | 13 | Sep 23, 2025 | |
| CYTK Cytokinetics | Maintains: Overweight | $53 → $71 | $50.40 | +40.87% | 3 | Sep 3, 2025 | |
| RGNX REGENXBIO | Maintains: Overweight | $50 → $37 | $9.65 | +283.42% | 7 | Aug 8, 2025 | |
| RNA Avidity Biosciences | Maintains: Overweight | $59 → $62 | $42.95 | +44.35% | 4 | Aug 8, 2025 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $42 → $56 | $61.67 | -9.19% | 17 | Aug 6, 2025 | |
| BEAM Beam Therapeutics | Maintains: Equal-Weight | $25 → $21 | $22.97 | -8.58% | 10 | Aug 6, 2025 | |
| MRNA Moderna | Maintains: Equal-Weight | $40 → $31 | $24.49 | +26.58% | 10 | Aug 4, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $329 → $460 | $446.40 | +3.05% | 8 | Aug 1, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Equal-Weight | $10 → $22 | $18.36 | +19.83% | 15 | Jul 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $42 → $46 | $58.99 | -22.02% | 16 | Jul 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $10 | $6.15 | +62.60% | 7 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $5 | $0.66 | +653.01% | 4 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $4 | $3.32 | +20.48% | 4 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $38 | $8.39 | +352.92% | 2 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $8 → $11 | $7.63 | +44.17% | 10 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $31 | $5.49 | +464.66% | 6 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 → $26 | $16.31 | +59.41% | 7 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $435 → $467 | $385.74 | +21.07% | 17 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $5 → $3 | $3.24 | -7.41% | 9 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $86 | $53.85 | +59.70% | 15 | Oct 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $81 | $29.08 | +178.54% | 6 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $94 | $33.37 | +181.69% | 6 | Jan 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $7 → $9 | $16.60 | -45.78% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $16 → $25 | $22.17 | +12.77% | 5 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $18 | $8.19 | +119.91% | 2 | May 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $21 → $9 | $4.84 | +85.95% | 6 | Aug 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $275 | $5.44 | +4,955.15% | 1 | Jan 6, 2017 |
Kodiak Sciences
Sep 25, 2025
Upgrades: Equal-Weight
Price Target: $7 → $17
Current: $15.80
Upside: +7.59%
Ionis Pharmaceuticals
Sep 23, 2025
Maintains: Overweight
Price Target: $78 → $80
Current: $64.09
Upside: +24.82%
Cytokinetics
Sep 3, 2025
Maintains: Overweight
Price Target: $53 → $71
Current: $50.40
Upside: +40.87%
REGENXBIO
Aug 8, 2025
Maintains: Overweight
Price Target: $50 → $37
Current: $9.65
Upside: +283.42%
Avidity Biosciences
Aug 8, 2025
Maintains: Overweight
Price Target: $59 → $62
Current: $42.95
Upside: +44.35%
CRISPR Therapeutics AG
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $42 → $56
Current: $61.67
Upside: -9.19%
Beam Therapeutics
Aug 6, 2025
Maintains: Equal-Weight
Price Target: $25 → $21
Current: $22.97
Upside: -8.58%
Moderna
Aug 4, 2025
Maintains: Equal-Weight
Price Target: $40 → $31
Current: $24.49
Upside: +26.58%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Overweight
Price Target: $329 → $460
Current: $446.40
Upside: +3.05%
Sarepta Therapeutics
Jul 30, 2025
Upgrades: Equal-Weight
Price Target: $10 → $22
Current: $18.36
Upside: +19.83%
Jul 29, 2025
Maintains: Equal-Weight
Price Target: $42 → $46
Current: $58.99
Upside: -22.02%
May 16, 2025
Maintains: Overweight
Price Target: $15 → $10
Current: $6.15
Upside: +62.60%
May 14, 2025
Maintains: Overweight
Price Target: $9 → $5
Current: $0.66
Upside: +653.01%
May 13, 2025
Maintains: Overweight
Price Target: $5 → $4
Current: $3.32
Upside: +20.48%
May 9, 2025
Maintains: Overweight
Price Target: $45 → $38
Current: $8.39
Upside: +352.92%
May 7, 2025
Maintains: Equal-Weight
Price Target: $8 → $11
Current: $7.63
Upside: +44.17%
Feb 28, 2025
Maintains: Overweight
Price Target: $26 → $31
Current: $5.49
Upside: +464.66%
Feb 28, 2025
Maintains: Overweight
Price Target: $55 → $26
Current: $16.31
Upside: +59.41%
Feb 11, 2025
Maintains: Equal-Weight
Price Target: $435 → $467
Current: $385.74
Upside: +21.07%
Dec 13, 2024
Maintains: Equal-Weight
Price Target: $5 → $3
Current: $3.24
Upside: -7.41%
Oct 4, 2024
Maintains: Overweight
Price Target: $110 → $86
Current: $53.85
Upside: +59.70%
Aug 5, 2024
Maintains: Overweight
Price Target: $83 → $81
Current: $29.08
Upside: +178.54%
Jan 24, 2024
Maintains: Overweight
Price Target: $93 → $94
Current: $33.37
Upside: +181.69%
Dec 22, 2022
Maintains: Equal-Weight
Price Target: $7 → $9
Current: $16.60
Upside: -45.78%
Nov 2, 2022
Upgrades: Equal-Weight
Price Target: $16 → $25
Current: $22.17
Upside: +12.77%
May 13, 2022
Maintains: Overweight
Price Target: $32 → $18
Current: $8.19
Upside: +119.91%
Aug 9, 2019
Maintains: Underweight
Price Target: $21 → $9
Current: $4.84
Upside: +85.95%
Jan 6, 2017
Initiates: Buy
Price Target: $275
Current: $5.44
Upside: +4,955.15%